Printer Friendly

HYDRON TECHNOLOGIES GRANTED EUR0PEAN PATENT ON NEW MOISTURIZING TECHNOLOGY

 BOCA RATON, Fla., Jan. 3 /PRNewswire/ -- Hydron Technologies, Inc. (NASDAQ: HTEC) announced today that it has been granted a European patent covering an emulsification process that makes a new moisturizing technology available to the pharmaceutical industry. The patent describes the only scientifically known means to suspend or emulsify the Hydron polymer in creams, lotions, balms and other emollients suitable for cosmetic and personal care products. Hydron, known chemically as polyhydroxyethyl methacrylate, is a hygroscopic or water-attracting polymer with superior moisture holding abilities.
 According to the patent, Hydron utilized in cosmetic emulsions creates a thin hygroscopic film that is not tacky, gummy, greasy or oily; has good tactility and flexibility; is not dissolved by sebaceous oils; readily penetrates into skin pores and provides a velvety smooth skin feel; and is moisture resistant but allows air and moisture permeability (breathability). The film is insoluble in water and resistant to rub-off, but can easily be removed with soap and water.
 Its applications within the pharmaceutical industry include more effective and prolonged delivery of moisturizing agents to the skin, water- and perspiration-resistant sunscreens, acid-resistant baby lotions, enhanced flavor and scent releasing components, and a drug delivery system for topically applied over-the-counter medications, such as analgesics, acne medications and anti-inflammatory ointments. Drugs penetrate the skin mr?e effectively in a moist environment. The Hydron emulsion system releases drugs from a cushion of moisture that remains on the skin's surface for prolonged periods of time, since it is not broken down by skin secretions such as perspiration or oil.
 Hydron Technologies (HyTech) has already been granted patents on its technology in the United States, Australia and South Africa. The company currently develops and manufactures a line of skin care products based on the Hydron emulsification system. The products will be marketed by QVC Network, Inc. (NASDAQ: QVCN) in North, South and Central America under a licensing agreement announced last month.
 HyTech retains the rights to market consumer products outside of QVC's territory and has worldwide rights to market all products to the health care field. The company is interested in forming strategic alliances with pharmaceutical firms to manufacture and distribute Hydron- based products in foreign markets, and to improve the effectiveness of topical OTC medications that are currently marketed domestically or overseas. Such products could benefit from HyTech's patent protection by utilizing the Hydron technology as a drug delivery system.
 The European patent, which will remain in force for 20 years, provides protection in Austria, Belgium, France, Germany, Great Britain, Greece, Italy, Luxembourg, Netherlands, Spain, Switzerland/Liechtenstein and Sweden. HyTech has identical patents pending in Canada, Japan and Israel.
 -0- 1/3/94
 /CONTACT: Karen Gray of Hydron Technologies, 407-994-6191/
 (HTEC QVCN)


CO: Hydron Technologies, Inc.; QVC Network, Inc. ST: Florida IN: HOU REA SU:

RK-AW -- FL001 -- 8432 01/03/94 10:08 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 3, 1994
Words:468
Previous Article:COMERICA BANK FORMS FULL-SERVICE BROKER DEALER
Next Article:CRUISE TO GIVE BEST OF FLORIDA AND MEXICO FOR FAMILIES
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters